Susquehanna International Group
SPRO icon

Susquehanna International Group’s Spero Therapeutics SPRO Stock Holding History

Susquehanna International Group’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68M Buy
759,290
+426,175
+128% +$1.11M ﹤0.01% 6880
2026
Q1 		$779K Buy
333,115
+39,415
+13% +$93.5K ﹤0.01% 8536
2025
Q4 		$684K Buy
+293,700
New +$682K ﹤0.01% 8079
2025
Q3 		– Sell
-69,814
Closed -$154K – 13789
2025
Q2 		$202K Buy
+69,814
New +$100K ﹤0.01% 11193
2025
Q1 		– Sell
-29,755
Closed -$30.6K – 13398
2024
Q4 		$30.6K Sell
29,755
-14,464
-33% -$17.2K ﹤0.01% 11834
2024
Q3 		$59.3K Buy
44,219
+21,146
+92% +$28.4K ﹤0.01% 11314
2024
Q2 		$30K Buy
+23,073
New +$34.8K ﹤0.01% 11564
2024
Q1 		– Sell
-18,086
Closed -$28.4K – 13268
2023
Q4 		$26.6K Sell
18,086
-2,097
-10% -$2.5K ﹤0.01% 11912
2023
Q3 		$24.4K Sell
20,183
-24,176
-55% -$33.5K ﹤0.01% 11550
2023
Q2 		$64.3K Buy
44,359
+17,815
+67% +$30.5K ﹤0.01% 11224
2023
Q1 		$38.5K Sell
26,544
-24,105
-48% -$40.4K ﹤0.01% 11813
2022
Q4 		$87.6K Sell
50,649
-18,637
-27% -$34.8K ﹤0.01% 11071
2022
Q3 		$139K Buy
69,286
+15,141
+28% +$15.1K ﹤0.01% 11344
2022
Q2 		$40K Sell
54,145
-12,939
-19% -$37.6K ﹤0.01% 12094
2022
Q1 		$584K Sell
67,084
-8,099
-11% -$83K ﹤0.01% 8580
2021
Q4 		$1.2M Buy
75,183
+35,435
+89% +$563K ﹤0.01% 6788
2021
Q3 		$732K Sell
39,748
-1,710
-4% -$27.4K ﹤0.01% 8384
2021
Q2 		$579K Sell
41,458
-27,725
-40% -$387K ﹤0.01% 9247
2021
Q1 		$1.02M Sell
69,183
-4,895
-7% -$86.1K ﹤0.01% 7695
2020
Q4 		$1.44M Buy
74,078
+16,670
+29% +$260K ﹤0.01% 5837
2020
Q3 		$641K Buy
57,408
+17,158
+43% +$203K ﹤0.01% 7148
2020
Q2 		$545K Buy
+40,250
New +$452K ﹤0.01% 7189
2019
Q4 		– Sell
-11,063
Closed -$117K – 10579
2019
Q3 		$117K Buy
+11,063
New +$117K ﹤0.01% 9477

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Susquehanna International Group's SPRO Position: Q2 2026 in Review

Susquehanna International Group increased its Spero Therapeutics (SPRO) stake by 128% in Q2 2026, buying an estimated $1.11M and bringing the position to 759,290 shares worth $1.68M. The position accounts for ﹤0.01% of the portfolio, ranked #6880.

Susquehanna International Group first reported a position in SPRO in Q3 2019 and has held it in 23 quarters since. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Susquehanna International Group held 759,290 shares of Spero Therapeutics worth $1.68M as of Q2 2026.
  • Susquehanna International Group bought 426,175 Spero Therapeutics shares in Q2 2026, an estimated $1.11M.
  • Spero Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #6880 holding.
  • Susquehanna International Group first reported a position in Spero Therapeutics in Q3 2019 and has held it in 23 quarters since.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.